Analyst Ratings For Abbott Laboratories
Portfolio Pulse from Benzinga Insights
Analyst ratings for Abbott Laboratories (NYSE:ABT) show a positive trend with 7 analysts offering diverse opinions over the last three months. The average 12-month price target has been raised to $129.43 from $125.00, indicating a 3.54% increase. Recent actions by analysts include ratings from 'Buy' to 'Outperform' with price target adjustments reflecting optimism about the company's performance. Abbott's financial metrics such as revenue growth, net margin, ROE, ROA, and debt management are highlighted, showcasing its strong market position and financial health.
April 03, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a positive outlook on Abbott Laboratories, raising the average 12-month price target to $129.43, indicating a bullish sentiment. Financial metrics such as revenue growth, net margin, ROE, ROA, and effective debt management underscore the company's strong performance and market position.
The positive adjustment in the 12-month price target for ABT by analysts, coupled with the company's strong financial metrics, indicates a bullish sentiment towards the stock. The consensus among analysts suggests confidence in the company's future performance, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100